Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5788030 | 0.81 | CYP3A4 (0.36) | CYP3A4TRPA1GABRA1GABRB2 | |
| SCHEMBL14270325 | 0.79 | — | — | |
| SCHEMBL3389301 | 0.74 | CYP3A4 (0.34) | CYP3A4TRPA1GABRA1GABRB2 | |
| SCHEMBL4774942 | 0.73 | CYP3A4 (0.36) | CYP3A4TRPA1GABRA1GABRB2 | |
| SCHEMBL1996913 | 0.73 | CYP3A4 (0.36) | CYP3A4TRPA1GABRA1GABRB2 | |
| SCHEMBL13079870 | 0.71 | — | — | |
| SCHEMBL1989667 | 0.70 | GABRA1 (0.37) | GABRA1GABRB2 | |
| SCHEMBL11786207 | 0.69 | TTR (0.36) | CYP3A4GABRA1GABRB2 | |
| SCHEMBL136454 | 0.67 | GABRA1 (0.36) | GABRA1GABRB2 | |
| SCHEMBL4860966 | 0.67 | GABRA1 (0.36) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481566-B2 | 4-Fluoro-6-methyl-1-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; for treatment of psychotic disorders and cognitive impairment | GLAXO GROUP LIMITED (GB) | 2013-07-09 | — | — | US | disclosed |
| US-8283364-B2 | Psyvhological disorders; cognition activators | GLAXO GROUP LIMITED (GB) | 2012-10-09 | — | — | US | disclosed |
| EP-1943230-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1943230-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2007036715-A2 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255195-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | CYP3A4 466/4885TRPA1 1599/4885GABRA1 179/4885 |
| US-20080058378-A1 | Compounds which have activity at M1 receptor and their uses in medicine. | CHRM1, CHRM2, CHRM5 | CYP3A4 498/4885TRPA1 1273/4885GABRA1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.